secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040643
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q2 revenue $117.3M (-3% YoY); withdraws FY2023 guidance on Medicare LCDs
--------------------------------------------------------------------------------

- Net revenue of $117.3M, down 3% YoY from $121.4M; net income $5.3M vs $8.7M.
- Adjusted net income $6.1M, adjusted EBITDA $15.4M; both down YoY.
- Withdrew FY2023 guidance due to Medicare LCDs from Novitas, First Coast Services, CGS limiting DFU/VLU coverage to only Apligraf and Dermagraft effective Sept 17, 2023.
- Cash and equivalents $89.5M, debt $69.0M as of June 30.
- Company engaging with relevant parties regarding LCDs; uncertain impact on revenue outlook.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000095017023040643/0000950170-23-040643-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000095017023040643/orgo-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040643

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer